Survival rate of prostate cancer in asian countries: A systematic review and meta-analysis

Background: Prostate cancer is one of the most common health issues among men, especially older men. In recent years, incidences of prostate cancer is increasing. Objective: The aim of this study was to provide a comprehensive estimate of the survival of prostate cancer in Asian countries. Methods: We searched five international databases including Medline/PubMed, Scopus, Embase, Web of Knowledge and ProQuest until June 1, 2018. The Newcastle-Ottawa Quality Assessment was used to evaluate the quality of selected papers. The review protocol was registered in PROSPERO (CRD42019117044). Results: A total of 714 titles were retrieved. Thirty-seven studies met the inclusion criteria. Based on the random-effect model one-year, five-year and ten-year survival rate of prostate cancer were 81 (95 CI 77.8�84.2), 61.9 (95 CI 59.5�64.3) and 36.2 (95 CI 9.2�63.2) respectively. Survival rates based on HDI level for five-year were 30.07, 43.43 and 70.84 percent for medium, high and very high levels, respectively. Conclusion: According to the results of our study, the prostate cancer survival rate in Asian countries is relatively lower than in Europe and North America. © 2020 The Author(s)

The survival rate of hepatocellular carcinoma in asian countries: A systematic review and meta-analysis

Hepatocellular carcinoma or Liver cancer (LC) is the sixth most common cancer and the fourth cause of death worldwide in 2018. There has not been a comprehensive study on the survival rate of patients with LC in Asia yet. Therefore, the present study was conducted to evaluate the survival rate of patients with LC in Asian countries. The methodology of the present study is based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement. The researchers searched five international databases including Medline/PubMed, Scopus, Embase, Web of Knowledge and ProQuest until July 1, 2018. We also searched Google Scholar for detecting grey literature. The Newcastle-Ottawa Quality Assessment Form was used to evaluate the quality of selected papers. A total of 1425 titles were retrieved. 63 studies met the inclusion criteria. Based on the random-effect model one-year, three-year and five-year survival rate of LC were 34.8 (95 CI; 30.3-39.3), 19 (95 CI; 18.2-21.8) and 18.1 (95 CI;16.1-20.1) respectively. According to the results of our study, the LC survival rate in Asian countries is relatively lower than in Europe and North America. © 2020, Leibniz Research Centre for Working Environment and Human Factors. All rights reserved

The incidence of bladder cancer in Iran: a systematic review and meta-analysis

Objective: There are several reports related to the incidence of bladder cancer (BC) from various geographical locations of Iran. Nevertheless, no comprehensive systematic review has conducted in this regard. Therefore, the present systematic review and meta-analysis carried out to estimate the incidence rate of BC among Iranian people. Patients and Methods: This systematic review was done based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) in October 2017. A search was performed in five international database (Medline/PubMed, Scopus, Embase, ISI/ Web of Science, and Google Scholar), and four national databases (Scientific Information Database, MagIran, Barakat Knowledge Network System, and IranDoc). The incidence rate of BC was calculated using random-effect model. Results: An aggregate of 226 papers was obtained in the primary search of the databases. After further refinement of the retrieved studies, 29 studies were included. The age-standardized rate of BC was 10.92, 95% CI (9.88-11.96) and, 2.80, 95% CI (2.47-3.13) in males and females, respectively. Conclusions: The incidence of BC was lower in Iran compared to other parts of the world. However, more investigations are needed to outline the exact incidence rate and the trend of BC among Iranian population

THE INCIDENCE OF NON-HODGKIN LYMPHOMA IN IRAN: A SYSTEMATIC REVIEW AND META-ANALYSIS

Objective: Non-Hodgkin's lymphoma (NHL) is one of the common cancers of the blood. The present study is conducted to evaluate the incidence rates of NHL in Iran. Patients and Methods: A systematic search was conducted on all published studies of NHL incidence using Medline/PubMed, Scopus, Embase, Web of sciences, and four Iranian databases (Scientific Information Database, MagIran, IranMedex, and IranDoc) until June 2018. This systematic review was done according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA). Results: After first searching 262 potentially relevant studies was yielded. A total of 9 studies were included. The results of the random effect model were demonstrated the age-standardized rate (ASR) of NHL was 4.43, 95% CI (2.76 to 6.11) among males and 2.79, 95 % CI (1.71 to 3.88) among females. Conclusions: In comparison with other geographical locations, the incidence of NHL is lower in Iran